Uncategorized

Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced the publication of two abstracts regarding MCLA-129 on the European Society for Medical Oncology Asia Congress website.

GE HealthCare will highlight more than 40 innovations, including several key artificial intelligence -enabled technologies within the Imaging, Ultrasound, and digital space at the Radiological Society of North America’s 2023 Annual Meeting taking place Nov. 26-30 in Chicago, IL.

Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, has published positive results from a human clinical trial involving its potentially game-changing technology that enables vaccines to be applied to the skin using a small patch, instead of using traditional needle and syringe.

Median Technologies unveils a new identity, including a new name, logo, tagline for its iBiopsy® AI/ML tech-based suite of software as medical devices and business unit, as part of an extensive rebranding initiative.

Konica Minolta Healthcare Americas, Inc., announced several new solutions in digital radiography and ultrasound that will be introduced at the 2023 Radiology Society of North America Scientific Assembly and Annual Meeting from November 26-30 in Chicago, IL.

Mesoblast Limited announced that it has filed for orphan drug designation and rare pediatric disease designation with the United States Food and Drug Administration for its allogeneic cell therapy Revascor® in the treatment of the congenital heart disease hypoplastic left heart syndrome.

While Amgen and Mirati are widely viewed as frontrunners to win the first front line approval, analysts—and competitors—say the field is still wide open.

As companies clamor for a piece of the antibody-drug conjugate pie, experts pose the question: is it possible to replicate the success of Enhertu?

Las estrategias y herramientas para predecir y retrasar la progresión a la enfermedad renal terminal son vitales

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) today announced the Company has received notice from The Nasdaq Capital Market, LLC (“Nasdaq”), dated November 22, 2023, informing Novo that it has regained compliance with the minimum bid price requirement as set forth under NASDAQ Listing Rule 5550(a)(2) for continued listing on Nasdaq.